. A Huan Kingdom mourned. It lasted for nearly half a month. For half a month, the TV basically had documentaries that were only made before, such as the life profile of the old man. From childhood to later on, he took up the position of the supreme leader. The ups and downs of the past few decades flashed one by one in more than a dozen episodes of documentaries.

As a person with a close relationship with the elder family, Fan Wubing naturally participated in the memorial service held later, especially after following the leader of the Politburo, he presented a wreath as an important friend.

After dealing with the matter here, Fan Wubing focused his main energy on negotiating the acquisition case with Haizhou Pharmaceutical Group. After several months of downsizing, Fan Wubing and Donghai Province came up with a solution. Bypassed the supervision of central ministries and commissions, they first released the research department of Haizhou Pharmaceutical Group. The Haizhou New Drug Research Institute was established, which was independently controlled by the government, and since then, the research department of Haizhou Pharmaceutical Group was established.

Later, Fan Investment Group reached a cooperation intention with Donghai Province. Fan Investment Group injected 100 million yuan and obtained 80% of the equity of the institute. Since then, it has become the new boss of this pharmaceutical research institution with a number of up to 500 people, mainly established with doctoral and master's degrees.

Because this case did not rise to the level of directly acquiring Haizhou Pharmaceutical Group, the supervision scope of central ministries and commissions was bypassed. After the forces that had oppose the acquisition of Haizhou Pharmaceutical Group came back to their senses, it was revealed that the situation was already done. Besides some criticism in the operation method, there was no suspicion of violations. Therefore, the main body of Haizhou Pharmaceutical Group had not moved. Fan's Investment Group only acquired a small part of the professional institutions that had been divided by the Donghai Provincial Government.

Moreover, the price of this small-scale acquisition is quite high. After all, the research institute not only has no profitability, but also requires investing a lot of money every year to maintain its operation. It can be said that it is a great burden for the entire Haizhou Pharmaceutical Group.

Before this, many people from Haizhou Pharmaceutical Group said that the company had so many researchers, but never produced any decent research results. Instead, large research expenses and personnel expenses dragged Haizhou Pharmaceutical Group to a shaky and overwhelmed. Therefore, some people had long wanted to abolish the research department. The company had this proposal on our behalf, but the group had never dared to take any action, for fear of causing some major problems.

After all, the situation of laid off the company in the past two years has caused a lot of trouble that affects local stability. At this time, from the company leaders to the local leaders, they are generally unwilling to touch the interests of this part.

At this time, Fan Wubing produced a taro; the leaders of Donghai Province, especially Wu Fukuan, who was eager to get closer to the Fan family, immediately made a decision. Respect the previous opinions of Haizhou Pharmaceutical Group, and independent research departments and take the path of market-oriented operation. The government and Fan's Investment Group jointly established a joint venture with the shareholders' research institute. The benefits of the output will also be divided by the two according to the equity ratio.

However, Fan's Investment Group also stated that with the continuous injecting new funds into the research institute, the proportion of equity held by the Donghai Provincial Government in the research institute will be diluted accordingly.

, "In other words, if Fan's capital injection exceeds one billion, the proportion of equity held by the Donghai Provincial Government in the research institute will be less than 2%?" After Shen Ying learned the news, she asked Fan Wubing. "It seems that you are determined to win this research department."

"That was very natural. Fan Wubing nodded and replied, "In fact, what I really care about is the research team of Haizhou Pharmaceutical Group. After all, the strength of this team is still very strong. It is just limited to the system and has not played the role he deserves. Now that he has turned his shares, I can use him to do a lot of things."

Fan Wubing has many good things in his hands, such as the secret recipe given to him by his teacher Fan Tianlan. These things can be operated through commercialization, making them more conducive to promotion, but turning traditional Chinese medicine preparations into tablets or capsules, oral liquids that are suitable for the current market demand requires repositioning, and some pathological tests and toxicity analysis are made. There are also various experimental requirements that need to meet the requirements of the International Organization for Standardization. Finally, a result that can enable the market promotion of new drugs is obtained.

All of this requires a professional research team to do, and it is not possible for one or two people to do it.

Fan Wubing seized time to promote new drug research and promotion, mainly because he felt the huge pressure on European and American drugs, and wanted to make the domestic drug market come to a bloody path and regain many lost traditional drug markets.

In recent years, it has been generally believed that the United States has overshadowed Europe in terms of drug research capabilities. However, according to the analysis of all data over the past 20 years, in terms of drug innovation, the United States has not surpassed Europe in the research efficiency of new drugs, and Europe's new drug research capabilities are still ahead of the United States. Compared with the new drugs previously prescribed, the clinical efficacy of most new drugs has not increased significantly.

Official and industry reports once generally believed that the United States had surpassed Europe in the prescribed new drugs. However, although the US Congress and a large number of investors were encouraging pharmaceutical companies to open and sell new drugs, these new drugs have no real value, and the efficacy of new drugs is only slightly smaller than that of old drugs.

.

The United States has been developing rapidly in the research of global drugs, innovators, biological products and orphan drugs, but Europe's research capabilities have hardly decreased, and Europe is still leading in opening and global high interest rates.

It is obvious that the United States has not had Europe in terms of the new compounds available.

The research ability and total research investment of drugs are often confused. A very typical propaganda is that since the beginning of the two thousand years, the United States has developed itself into a major innovator in pharmaceuticals. This statement stems from the fact that the United States invests more funds in the research department, but it is still unknown how many real new ideas are there in the U.S. laboratories.

Moreover, many responsible experts say that the conclusion that most new drugs are of high quality or are important to patients is untenable.

From the perspective of patients, doctors and health policies, quality means that new drugs are clinically more effective or have fewer side effects than existing drugs. However, many current survey reports do not use data or treatment results to evaluate the quality of new drugs. Advertisements of some new drugs have obviously misled consumers and promoted the significant effect of new drugs, and from the perspective of the clinical practice of patients taking the drugs, the efficacy of both is almost the same

In short, commercial success often does not equate to a significant improvement in efficacy.

At present, companies do need to encourage companies to prescribe new drugs that are better than existing drugs than existing drugs. Instead of prescribing drugs that are just a little better than placebo. Therefore, some scholars suggest that independent clinical trials be sponsored by public institutions such as the National Institute of Health in the United States. This can compare the advantages and risks with existing treatment methods. Publicly sponsored trials can also reduce costs and risks for manufacturers, and improve the research and competitive capabilities of small factories by reducing high-cost barriers to improve the research capabilities and competitiveness of small factories by reducing high-cost barriers.

.

, "Now the government has completely relaxed the approval of new drugs. There are probably no less than 20,000 new drugs released every year, but there are really no new drugs, and there are not even a hundred of them. The others are old drugs that are replaced after changing the packaging and are launched under a new name. When Fan Wubing mentioned this issue, he said to Shen Ying, "For example, the drugs that often appear in TV advertisements are actually upgraded versions of very simple cold powders, or they are simply the same thing that has changed the packaging method. Not only has the effect not improved, or it has also been reduced, but the price is several times or dozens of times higher than the original product. This is very unfavorable for consumers who don't know the truth."

Fan Wubing is very clear that in response to the current problems of domestic innovative drug research companies not paying enough attention, insufficient investment, and not keeping up with basic research, we need to change this situation. It is not possible to rely on the government, and it is impossible to say that we can only do some things ourselves.

To rank among the world's leading talents in the research and production of innovative drugs, we must first create a group of outstanding talents, including excellent technical talents and management talents. Therefore, what should be solved first is the problem of the basic application and incentive mechanism for scientific researchers, and explore the options and equity issues of scientists when intangible assets are invested. This mainly includes scientific researchers within scientific research institutes and enterprises.

After all, the research on innovative drugs will eventually go to the forefront. In addition to requiring excellent technical talents, an excellent team of management talents must also be created.

In addition to solving the problem of talent, we must strengthen basic research and lay a solid foundation for the successful research of innovative drugs. Almost all governments in advanced countries use their main funds to support basic research, and the funds for applying basic and research are mainly invested by enterprises, and the same is true for the research of innovative drugs.

However, due to many reasons such as the system and mechanism, the state-owned and state-controlled enterprises that currently dominate the current position are difficult to become the main body of innovation. Generally speaking, the current strength of such enterprises to spend huge amounts of money on original innovative drug research is still insufficient.

Therefore, at this stage, it is necessary to push the achievements accumulated by various research institutes over the years to industrialization as soon as possible, and set up some major industrialization projects to support it. And with the universal and effective establishment of the modern enterprise system, the investment strength of a number of enterprises has increased, and enterprises will definitely become the main body of scientific and technological innovation, which is inevitable.

Now Fan Wubing has just taken this path ahead of time to strengthen the research efforts of domestic innovative drugs as soon as possible so as not to lag too much behind foreign peers.

New technologies have become the origin and an indispensable and important part of the research of new drugs. Tracking cutting-edge key technologies is very important for the development of innovative drugs. Based on the latest achievements of the human genome, high-tech technologies for drug research such as molecular biology, structural biology, computer-assisted virtual screening, combination chemistry and high-throughput screening are integrated. Establish a platform for innovative drugs and practice in a variety of target protein systems related to important diseases. This is a good idea.

New drug research is actually a system project, guiding the establishment of a centralized creation of new drug high-tech platforms, and the formation of a research group composed of high-level interdisciplinary researchers, improving the innovative drug research system, and strengthening the construction of key bottleneck technology platforms. Such as preparation technology, drug reagent platforms, etc., these are not problems that current state-owned enterprises can solve.

But what happened later was a bit ridiculous. After seeing that Fan's Investment Group seemed to have little interest in acquiring Haizhou Pharmaceutical Group, the cadres and employees of Haizhou Pharmaceutical Group were very disappointed. After all, everyone is very clear about the current situation of Haizhou Pharmaceutical Group. If strategic investors are not introduced, they will probably not be able to hold on soon.

The so-called annual sales exceeding 10 billion yuan is just a saying. At this time, the group's profits have been declining. The debt ratio has been rising. If there is no breakthrough, everyone will go to drink the northwest wind next year.

When Fan's Investment Group had an intention to acquire, as employees of Haizhou Pharmaceutical Group, they were very willing, because everyone has known that the major companies acquired by Fan's now have an advantageous living standard in the local area. If Haizhou Pharmaceutical Group is successfully acquired by Fan's, there will be no exception.

But no one expected that the acquisition case was stopped by the central ministries and commissions, and everyone's thoughts turned into a bubble. It was really unacceptable. Seeing that the group's least popular research department gave the order another, many people were happy and thought that they had finally lost a big burden.

But Fan's Investment Group actually acquired the independent Haizhou New Drug Research Institute, which is surprising. Compared with the New Drug Research Institute, which requires a large amount of support funds, the manufacturer can directly generate part of the revenue?!

Fan's ideas are always unpredictable.

However, after confirming through internal relations that Fan is no longer interested in the acquisition of Haizhou Pharmaceutical Group, most of the employees of Haizhou Pharmaceutical Group were a little angry, believing that the inaction of the central ministries and commissions has increased the risks they face. If Haizhou Pharmaceutical Group goes bankrupt next year, aren’t they all going to be laid off?

Although leaders can escape in advance and work in another place, what other people can have? As technical workers who have become professional, they are actually the lowest-level existence in this society. What jobs can they find without the companies they can work for?
Chapter completed!